Alerts will be sent to your verified email
Verify EmailTHEMISMED
Themis Medicare
|
NGL Fine-Chem
|
Kopran
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
3.26 % | 1.8 % | n/a |
Financials
|
|||
5 yr Average ROE
|
15.48 % | 18.68 % | 12.69 % |
5yr average Equity Multiplier
|
1.56 | 1.37 | 1.57 |
5yr Average Asset Turnover Ratio
|
0.71 | 1.03 | 0.87 |
5yr Avg Net Profit Margin
|
13.75 % | 12.56 % | 8.93 % |
Price to Book
|
2.37 | 3.08 | 1.48 |
P/E
|
0.0 | 41.64 | 22.0 |
5yr Avg Cash Conversion Cycle
|
62.99 Days | 24.74 Days | 100.24 Days |
Inventory Days
|
69.58 Days | 47.94 Days | 84.74 Days |
Days Receivable
|
159.79 Days | 84.83 Days | 123.83 Days |
Days Payable
|
137.27 Days | 83.75 Days | 98.33 Days |
5yr Average Interest Coverage Ratio
|
7.27 | 25.7 | 10.74 |
5yr Avg ROCE
|
17.31 % | 24.83 % | 17.11 % |
5yr Avg Operating Profit Margin
|
18.07 % | 18.08 % | 13.59 % |
5 yr average Debt to Equity
|
0.28 | 0.16 | 0.22 |
5yr CAGR Net Profit
|
-3.53 % | -18.08 % | -8.95 % |
5yr Average Return on Assets
|
9.9 % | 13.76 % | 7.93 % |
Shareholdings
|
|||
Promoter Holding
|
67.15 % | 72.74 % | 44.42 % |
Share Pledged by Promoters
|
2.43 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.03 % | -1.07 % | 0.17 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Themis Medicare
|
NGL Fine-Chem
|
Kopran
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Verticals
|
Verticals
|
-
|
-
|